Mantle cell lymphoma · 8 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
R-BEAM Variant #01 Partial | — | R 56 156 | — | — | — | ~1 | ~R 56 156 indirect | — |
CBV Variant #01 Partial | — | R 9 597 | — | — | — | ~1 | ~R 9 597 PFS proxy · indirect | 2 |
BEAC Variant #01 Partial | — | R 7 009 | — | — | — | ~1 | ~R 7 009 indirect | — |
BEAM Variant #01 Partial | — | R 4 346 | — | — | — | ~1 | ~R 4 346 indirect | — |
Cyclophosphamide and TBI Variant #01 | — | R 1 176 | — | — | 90.0 mo | 1 | R 1 176 PFS proxy | 1 |
Melphalan and TBI Variant #01 | — | — | — | — | — | ~1 | — | — |
TAM6 Variant #01 | — | — | — | — | — | ~1 | — | — |
Ibritumomab tiuxetan protocol Variant #18 Partial | — | — | 8d | ~36.5 mo | — | ~1 | — | 1 |
8 of 8 regimens shown